Beta

Neuropace, inc.NPCE.US Overview

US StockHealthcare
(No presentation for NPCE)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

NPCE AI Insights

NPCE Overall Performance

NPCE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NPCE Recent Performance

-2.09%

Neuropace, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

NPCE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check NPCE's Trend

NPCE Key Information

NPCE Valuation Metrics

NPCE Profile

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Price of NPCE

NPCE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NPCE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.64
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
5.70
PB Ratio
29.97
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
77.23%
Net Margin
-21.47%
Revenue Growth (YoY)
25.13%
Profit Growth (YoY)
30.69%
3-Year Revenue Growth
27.63%
3-Year Profit Growth
32.72%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.64
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
5.70
PB Ratio
29.97
Price-to-FCF
-
Gross Margin
77.23%
Net Margin
-21.47%
Revenue Growth (YoY)
25.13%
Profit Growth (YoY)
30.69%
3-Year Revenue Growth
27.63%
3-Year Profit Growth
32.72%
  • When is NPCE's latest earnings report released?

    The most recent financial report for Neuropace, inc. (NPCE) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NPCE's short-term business performance and financial health. For the latest updates on NPCE's earnings releases, visit this page regularly.

  • What is the operating profit of NPCE?

    According to the latest financial report, Neuropace, inc. (NPCE) reported an Operating Profit of -1.77M with an Operating Margin of -6.65% this period, representing a growth of 51.63% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is NPCE's revenue growth?

    In the latest financial report, Neuropace, inc. (NPCE) announced revenue of 26.59M, with a Year-Over-Year growth rate of 23.86%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does NPCE have?

    As of the end of the reporting period, Neuropace, inc. (NPCE) had total debt of 70.84M, with a debt ratio of 0.67. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does NPCE have?

    At the end of the period, Neuropace, inc. (NPCE) held Total Cash and Cash Equivalents of 21.81M, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does NPCE go with three margins increasing?

    In the latest report, Neuropace, inc. (NPCE) did not achieve the “three margins increasing” benchmark, with a gross margin of 77.4%%, operating margin of -6.65%%, and net margin of -10.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NPCE's profit trajectory and future growth potential.

  • Is NPCE's EPS continuing to grow?

    According to the past four quarterly reports, Neuropace, inc. (NPCE)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NPCE?

    Neuropace, inc. (NPCE)'s Free Cash Flow (FCF) for the period is 409K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 108.46% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of NPCE?

    The latest valuation data shows Neuropace, inc. (NPCE) has a Price-To-Earnings (PE) ratio of -21.69 and a Price/Earnings-To-Growth (PEG) ratio of 1.8. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.